

## Spotlight on Parkinson's Disease: The ABC's of DBS



## **Biography**



Jill L. Ostrem, MD

Professor of Neurology

Division Chief, UCSF Movement Disorder and Neuromodulation Center

Weill Institute for Neurosciences

University of California San Francisco

San Francisco, CA

Dr. Jill Ostrem is a movement disorder neurologist and Medical Director and Division Chief of the UCSF Movement Disorders and Neuromodulation Center. She has a special interest in the medical and surgical treatment of movement disorders including Parkinson's disease, Dystonia, and Tremor. She earned her medical degree from George Washington University and did her residency and movement disorders fellowship at UCLA.

She joined UCSF in 2003. She has helped establish an internationally recognized multidisciplinary clinical, research, and training Center for the medical and surgical treatment of movement disorders. The Center is unique in that its creation and growth has been supported from both the Departments of Neurology and Neurosurgery, with the founding goal of offering a cutting-edge technology, deep brain stimulation therapy, to movement disorders patients. Today, the clinical program offers comprehensive evaluation of movement disorder patients (Parkinson's disease, dystonia, tremor, atypical parkinsonism, and other diseases), multidisciplinary medical and surgical management of movement disorder patients (including neuropsychology and psychiatry), and botulinum neurotoxin injection therapy. The Center is now one of the most experienced Centers in the world in treating dystonia and Parkinson's disease (PD) patients with deep brain stimulation (DBS), and in performing physiological studies of the brain, both acutely during DBS surgery and chronically using implanted neural interfaces. Current research focuses on technical innovations in surgery for movement disorders, development of new DBS systems, old and new therapeutic brain targets for stimulation, innovations in clinical care (telehealth and palliative care clinical models), and experimental therapeutics for movement disorders.